ARBS: Strong H1 2024 growth in revenue and profit, with optimism for continued expansion

About this update from Arterra Bioscience Spa

Revenue grew 41% year-over-year in H1 2024, with EBITDA up 33% and net profit more than doubling. Positive sales trends and a new joint venture support a confident outlook for 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Arterra Bioscience Spa